Home › Funds › Opus Capital Group, LLC › SLS

Opus Capital Group, LLC position in SLS

SELLAS LIFE SCIENCES GROUP I · Health Care

Opus Capital Group, LLC reported holding 403,635 shares of SLS (SELLAS LIFE SCIENCES GROUP I) in its Q3 2026 13F filing — a position valued at US$5.0M, representing 0.49% of its reported portfolio and ranking #34 among its reported holdings. Opus Capital Group, LLC has disclosed SLS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)403.63K sh
Reported value held$4.97M
Portfolio Weight0.49%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Opus Capital Group, LLC's SLS position evolved

Opus Capital Group, LLC first disclosed a stake in SLS in Q3 2023 at 34,500 shares (US$57K). The position peaked in Q2 2026 at 385,604 shares, worth US$5.7M. Across 13 filings, Opus Capital Group, LLC increased the stake 10 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 403,635 shares valued at US$5.0M — an increase of 18,031 shares quarter over quarter.. Notable position changes include a 291% increase in Q4 2023 (shares fell 5% over the following quarter), a 49% increase in Q1 2024 (shares rose 18% over the following quarter), a 27% increase in Q4 2025 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 34.50K $57.00K New
Q4 2023 135.00K $143.00K Add
Q1 2024 200.60K $203.00K Add
Q2 2024 221.00K $263.00K Add
Q3 2024 226.10K $283.00K Add
Q4 2024 238.50K $248.00K Add
Q1 2025 239.50K $259.00K Hold
Q2 2025 240.00K $526.00K Hold
Q3 2025 250.00K $403.00K Add
Q4 2025 317.10K $1.20M Add
Q1 2026 346.45K $1.47M Add
Q2 2026 385.60K $5.69M Add
Q3 2026 403.63K $4.97M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SLS and 13F data

SLS (SELLAS LIFE SCIENCES GROUP I) is a Health Care company. 106 other funds we track also report a position in SLS — the largest reported positions include Sio Capital Management, LLC (US$18.2M), DAGCO, INC. (US$16.5M), Anson Funds Management LP (US$11.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SLS

All SLS fund holders →

FAQ

How long has Opus Capital Group, LLC held SLS?

Opus Capital Group, LLC has disclosed SLS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Opus Capital Group, LLC's current position in SLS?

As of Q3 2026, Opus Capital Group, LLC holds 403.63K shares of SLS (SELLAS LIFE SCIENCES GROUP I), valued at $4.97M, representing 0.49% of its reported portfolio and ranking #34.

Has Opus Capital Group, LLC been buying or selling SLS?

In the latest 13F filing (Q3 2026), Opus Capital Group, LLC increased its position in SLS. The position peaked in Q2 2026 at 385.60K shares.

Which other funds hold SLS?

Other major institutional holders of SLS include Sio Capital Management, LLC, DAGCO, INC., Anson Funds Management LP, among 106 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.